-
![Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide](/abs-image/US/2004/03/16/US06706710B2/abs.jpg.150x150.jpg)
1.发明授权Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide 失效（R）-N- [5-甲基-8-（4-甲基哌嗪-1-基）-1,2,3,4-四氢-2-萘基] -4-吗啉代苯甲酰胺公开(公告)号：US06706710B2
公开(公告)日：2004-03-16
申请号：US10333286
申请日：2003-01-17
IPC分类号： A61K315327
CPC分类号： C07D295/135
摘要： This invention relates to a novel form of a scrotonin h5-HT1B-receptor antagonist, namely a novel form of a salt of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,2,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide referred to as (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide monohydrobromide Form A. The invention also relates to processes for preparation of said of Form A, which form has a potential use after suitable pharmaceutical formulation in medical treatment, preferably in CNS disorders, over active bladder or vasospam, or growth control of tumors.
摘要翻译： 本发明涉及一种新型形式的角质蛋白h5-HT1B受体拮抗剂，即（R）-N- [5-甲基-8-（4-甲基哌嗪-1-基） 称为（R）-N- [5-甲基-8-（4-甲基哌嗪-1-基）-1,2,3,4-四氢-2-萘基] -4-吗啉代苯甲酰胺， 四氢-2-萘基] -4-吗啉代苯甲酰胺单氢溴酸盐形式A.本发明还涉及制备所述形式A的方法，该形式在药物治疗中优选在CNS障碍中的适当药物制剂之后具有潜在用途，超过活性膀胱 或血管紧张素，或肿瘤的生长控制。
-
公开(公告)号：US08008294B2
公开(公告)日：2011-08-30
申请号：US12162540
申请日：2007-01-31
申请人： Tesfai Sebhatu , Erica Ståhle
发明人： Tesfai Sebhatu , Erica Ståhle
IPC分类号： A61K31/5377 , C07D413/14
CPC分类号： C07D401/04
摘要： The salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing it and the use of it in therapy, and particularly in the therapy of GSK3 related conditions and disorders.
摘要翻译： 盐，2-羟基-3- [5-（吗啉-4-基甲基）吡啶-2-基] -1H-吲哚-5-甲酸柠檬酸盐，其制备方法，含有它的药物制剂及其用途 在治疗中，特别是治疗GSK3相关病症和疾病。
-
搜索结果
2 条记录 (耗时 0.022 秒)
